Compare Prologis Inc (PLD) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs Zimmer Biomet Holdings Inc — how do they compare? Prologis Inc trades at $128.59 (market cap $122.87B), while Zimmer Biomet Holdings Inc trades at $88.96 (market cap $16.95B). The key difference: Prologis Inc is far larger — about 7.2× Zimmer Biomet Holdings Inc's market cap, and Prologis Inc pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Prologis Inc for 102 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| PLD | ZBH | |
|---|---|---|
Market Cap | $122.87B | $16.95B |
Volume | 4,222,957 | 2,505,240 |
Sector | Real Estate | Health |
52-Week High | $149.96 | $103.98 |
52-Week Low | $111.23 | $79.58 |
Typical Hold Time | 102 Days | 89 Days |
Enterprise Value | $157.61B | $24.02B |
Dividend Yield | 3.31% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $127.3, down 1.07% on the day, amid a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is steady, supported by robust leasing activity and data center expansion, while profitability remains high with a net income margin of 45.79%. Analyst consensus is bullish with a $155.15 price target, though technical indicators show near-term pressure.
The outlook for PLD is positive due to its leading position in industrial real estate, driven by e-commerce and data center demand. Risks include rising debt levels and market volatility. Institutional buying and strong analyst support suggest long-term upside, but investors should monitor debt management and macroeconomic trends affecting REIT valuations.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
